Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? / Peter Hajek (2013)  

Public Titre : Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? : a randomised controlled trial Type de document : texte imprimé Auteurs : Peter Hajek, Auteur ; Katie Myers Smith, Auteur ; Al-Rehan Dhanji, Auteur ; Hayden McRobbie, Auteur Editeur : BioMed Central Année de publication : 2013 Collection : BMC Medicine, ISSN 1741-7015 Importance : p. 7 Langues : Français (fre) Catégories : [TABAC] étude:recherche:recherche clinique:essai clinique randomisé [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:patch à la nicotine [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3 Approche pharmacologique Résumé : Background Nicotine replacement therapy (NRT) and varenicline are both effective in helping smokers quit. There is growing interest in combining the two treatments to improve treatment outcomes, but no experimental data exist on whether this is efficacious. This double-blind randomised controlled trial was designed to evaluate whether adding nicotine patches to varenicline improves withdrawal relief and short-term abstinence rates. Methods 117 participants seeking help to stop smoking were randomly allocated to varenicline plus placebo patch or varenicline plus nicotine patch (15 mg/16 hour). Varenicline use commenced one week prior to the target quit date (TQD), patch use started on the TQD. Ratings of urges to smoke and cigarette withdrawal symptoms were collected weekly over 4 weeks post-TQD. Medication use and smoking status were established at 1, 4 and 12 weeks. Participants lost to follow-up were included as continuing smokers. Results 92% of participants used both medications during the first week after the TQD. The combination treatment generated no increase in nausea or other adverse effects. It had no overall effect on urges to smoke or on other withdrawal symptoms. The combination treatment did not improve biochemically validated abstinence rates at 1 week and 4 weeks post-TQD (69% vs 59%, p=0.28 and 60% vs 59%, p=0.91, in the nicotine patch and placebo patch arm, respectively), or self reported abstinence rates at 12 weeks (36% vs. 29%, p=0.39, NS). Conclusions The efficacy of varenicline was not enhanced by the addition of nicotine patches, although further trials would be useful to exclude the possibility of type II error. En ligne : https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-140 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7445

Aucun avis, veuillez vous identifier pour ajouter le vôtre !